Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 17/20 | 0.86 |
| ▸ | MET | P08581 | 10/20 | 0.86 |
| ▸ | MERTK | Q12866 | 2/20 | 0.86 |
| ▸ | PLK4 | O00444 | 1/20 | 0.86 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.86 |
| ▸ | RET | P07949 | 1/20 | 0.86 |
| ▸ | KDR | P35968 | 1/20 | 0.86 |
| ▸ | FLT3 | P36888 | 1/20 | 0.86 |
| ▸ | MST1R | Q04912 | 1/20 | 0.86 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.86 |
| ▸ | CAMK4 | Q16566 | 1/20 | 0.86 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.86 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.86 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.86 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23629546 | 0.95 | AXL (0.86) | AXLMETMERTKPLK4NTRK1 | |
| Merestinib SCHEMBL29493094 | 0.92 | AXL (1.00) | AXLMETMERTKPLK4NTRK1 | |
| Merestinib SCHEMBL679002 | 0.92 | AXL (1.00) | AXLMETMERTKPLK4NTRK1 | |
| Merestinib SCHEMBL680728 | 0.92 | AXL (0.99) | AXLMETMERTKPLK4NTRK1 | |
| Merestinib SCHEMBL29726013 | 0.92 | AXL (0.99) | AXLMETMERTKPLK4NTRK1 | |
| SCHEMBL23629471 | 0.92 | AXL (0.88) | AXLMETMERTKPLK4NTRK1 | |
| SCHEMBL23629478 | 0.91 | AXL (0.87) | AXLMETMERTKPLK4NTRK1 | |
| SCHEMBL23629434 | 0.91 | AXL (0.87) | AXLMETMERTKPLK4NTRK1 | |
| SCHEMBL23629476 | 0.91 | AXL (0.86) | AXLMETMERTKPLK4NTRK1 | |
| SCHEMBL23629405 | 0.91 | AXL (0.86) | AXLMETMERTKPLK4NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190336599-A1 | COMBINATION OF RAMUCIRUMAB AND MERESTINIB FOR USE IN TREATMENT OF COLORECTAL CANCER | ELI LILLY AND COMPANY (US) | 2019-11-07 | — | — | US | disclosed |
| US-20180207268-A1 | COMBINATION THERAPY FOR CANCER | IMCLONE LLC (US) | 2018-07-26 | — | — | US | disclosed |
| US-20180207268-A1 | COMBINATION THERAPY FOR CANCER | IMCLONE LLC (US) | 2018-07-26 | — | — | US | disclosed |
| WO-2017027544-A1 | COMBINATION THERAPY FOR CANCER | IMCLONE LLC (US) | 2017-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180207268-A1 | COMBINATION THERAPY FOR CANCER | FLT4, KDR, TEK | AXL 68/4885MET 9/4885MERTK 58/4885 |
| US-20190336599-A1 | COMBINATION OF RAMUCIRUMAB AND MERESTINIB FOR USE IN TREATMENT OF COLORECTAL CANCER | KDR, FLT4, FLT1 | AXL 38/4885MET 5/4885MERTK 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.